March 22, 2024Cancer Research

Progestin Formulations in Hormonal Contraception and Early-Onset Breast Cancer Risk

View Full Paper

Ask AI

Bookmark

Authors

LTLauren R. TerasAmerican Cancer Society EDEmily L. DeublerAmerican Cancer Society MSMark E. ShermanAmerican College of Cardiology

Discussion

Member takes

Implication

Cohort study reveals increased breast cancer risk from long-term oral contraceptives in premenopausal women, highlighting risks tied to specific progestin types.

Key Points

Long-term oral contraceptives increase early-onset breast cancer risk, and the observed risk varies considerably across different progestin formulations.
Prolonged oral contraceptives generate hazard ratios of 1.66 for breast cancer, whereas formulations containing norgestrel reach a higher ratio of 2.82.
Cohort analysis of 101,838 women highlights progestin-dependent risks, calling for hormonal contraception formulations that minimize early breast cancer.

Cite This Study

Teras et al. (2024) studied this question.

synapsesocial.com/papers/68e72f4bb6db6435876a873e https://doi.org/10.1158/1538-7445.am2024-3442

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals increased breast cancer risk from long-term oral contraceptives in premenopausal women, highlighting risks tied to specific progestin types.

Progestin Formulations in Hormonal Contraception and Early-Onset Breast Cancer Risk

Discussion

Member takes

Implication

Key Points

Cite This Study

Progestin Formulations in Hormonal Contraception and Early-Onset Breast Cancer Risk

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider